The new Right To Try (RTT) legislation presents an alternative for eligible individuals to seek drug coverage for treatment options which have only passed Phase I clinical trials. Specifically, the RTT law will allow terminally ill patients with physician approval to request access to experimental drugs which have completed Phase I clinical trials while protecting manufacturers and physicians from liability stemming from such use. Existing regulations have been in place for years regarding the expanded use of certain drugs, so how might this RTT legislation impact the current rules. Many wonder whether the new RTT law could be an opportunity that plans may leverage when it comes to benefit coverage. If coverage is extended by plans for drugs covered pursuant to the RTT regulations, what possible impacts may exist and what language may need to be modified within the plan materials? These questions and more are addressed within The Phia Group’s analysis on the issue. Click HERE to download The Phia Group’s comprehensive memo regarding the new RTT regulations. The Phia Group will also be hosting a podcast on this very issue, which will be available early next week.